Immunoglobulin G1 [De-236-Glycine,De-C-Terminal Lysine], Anti-(Human Cd40 Antigen) (Human Monoclonal Lvgn7409 ?1-Chain), Disulfide With Human Monoclonal Lvgn7409 ?-Chain, Dimer
Head And Neck Carcinoma
Explore 44 assets in Head And Neck Carcinoma →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05075993CT.gov Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Head And Neck Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1 [De-236-Glycine,De-C-Terminal Lysine], Anti-(Human Cd40 Antigen) (Human Monoclonal Lvgn7409 ?1-Chain), Disulfide With Human Monoclonal Lvgn7409 ?-Chain, Dimer (this asset) | M.D. Anderson Cancer Center | P1 | CC · 43 |
| Cyclophosphamide | National Cancer Institute (NCI) | P2 | BB |
| Pembrolizumab | National Cancer Institute (NCI) | P2 | BB |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Tadalafil | University of California, San Diego | P2 | B |
| Sapanisertib | National Cancer Institute (NCI) | P2 | CCC |
| Rain-32 | Rain Oncology Inc | P2 | CCC |
| Ulixertinib | National Cancer Institute (NCI) | P2 | CCC |
| Vismodegib | National Cancer Institute (NCI) | P2 | CCC |
+42 more in the Head And Neck Carcinoma cohort
Other indications for Immunoglobulin G1 [De-236-Glycine,De-C-Terminal Lysine], Anti-(Human Cd40 Antigen) (Human Monoclonal Lvgn7409 ?1-Chain), Disulfide With Human Monoclonal Lvgn7409 ?-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Esophageal Cancer | — | P1 | CC · 43 |
| Hepatocellular Carcinoma | — | P1 | CC · 43 |
| Ovarian Carcinoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1 [De-236-Glycine,De-C-Terminal Lysine], Anti-(Human Cd40 Antigen) (Human Monoclonal Lvgn7409 ?1-Chain), Disulfide With Human Monoclonal Lvgn7409 ?-Chain, Dimer in Head And Neck Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-de-236-glycinede-c-terminal-lysine-anti-human-cd40-antigen-human-monoclonal-lvgn7409-1-chain-disulfide-with-human-monoclonal-lvgn7409-chain-dimer-head-and-neck-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →